274 related articles for article (PubMed ID: 24707992)
1. Regorafenib-induced hyperammonemic encephalopathy.
Kuo JC; Parakh S; Yip D
J Clin Pharm Ther; 2014 Aug; 39(4):446-8. PubMed ID: 24707992
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
3. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib in gastrointestinal stromal tumors.
Sirohi B; Philip DS; Shrikhande SV
Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
[TBL] [Abstract][Full Text] [Related]
6. Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.
Quirino M; Rossi S; Schinzari G; Basso M; Strippoli A; Cassano A; Barone C
Medicine (Baltimore); 2017 Apr; 96(16):e6522. PubMed ID: 28422839
[TBL] [Abstract][Full Text] [Related]
7. Single dose regorafenib-induced hypertensive crisis.
Yilmaz B; Kemal Y; Teker F; Kut E; Demirag G; Yucel I
Exp Oncol; 2014 Jun; 36(2):134-5. PubMed ID: 24980770
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK
Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
[TBL] [Abstract][Full Text] [Related]
10. Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.
Kongsuphon N; Soukavanitch M; Teeraaumpornpunt N; Konmun J; Ativitavas T; Ngamphaiboon N
J Gastrointest Cancer; 2019 Sep; 50(3):601-603. PubMed ID: 29411249
[No Abstract] [Full Text] [Related]
11. Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report.
Akamine T; Ando K; Oki E; Saeki H; Nakashima Y; Imamura YU; Ohgaki K; Maehara Y
Anticancer Res; 2015 Jul; 35(7):4037-41. PubMed ID: 26124352
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Shirley M; Keating GM
Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.
Schvartsman G; Wagner MJ; Amini B; Zobniw CM; Trinh VA; Barbo AG; Lin HY; Wang WL; Conley AP; Ravi V; Araujo DM; Zarzour MA; Benjamin RS; Patel S; Somaiah N
Sci Rep; 2017 Aug; 7(1):9519. PubMed ID: 28842575
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
15. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
[No Abstract] [Full Text] [Related]
16. Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example.
García-Díaz HC; Eremiev S; Gómez-Alonso J; Veas Rodriguez J; Farriols A; Carreras MJ; Serrano C
J Oncol Pharm Pract; 2024 Apr; 30(3):576-583. PubMed ID: 38258317
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
Komatsu Y; Doi T; Sawaki A; Kanda T; Yamada Y; Kuss I; Demetri GD; Nishida T
Int J Clin Oncol; 2015 Oct; 20(5):905-12. PubMed ID: 25655899
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.
Prescrire Int; 2015 Oct; 24(164):234. PubMed ID: 26594725
[TBL] [Abstract][Full Text] [Related]
19. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
Chan SL; Ma BB
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
Saito Y; Takahashi T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Gan To Kagaku Ryoho; 2018 Jan; 45(1):121-123. PubMed ID: 29362328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
